In mutiple clinical trials, patients undergoing neuroAD Therapy System treatment have demonstrated measurable cognitive improvement following 6 weeks of 1-hr daily sessions. The results, published in peer-reviewed journals and presented at international congresses and symposia, indicated marked reversal of disease progression. Furthermore, double-blind, randomized, clinical trials, performed at the Beth Israel Deaconess Medical Center (Harvard Medical School, Boston, MA), in Israel, and in other locations showed statistically significant clinical results, compared with placebo. These results indicate measurable cognitive improvement after just a few weeks of treatment that has shown to last for up to one year.
Similar results were demonstrated on follow-up of patients who underwent neuroAD treatment in private clinic settings, both in Europe and in Israel.
Beneficial effect of repetitive transcranial magnetic stimulation combined with cognitive training for the treatment of Alzheimer-a proof of concept study (Rabey, 2010).pdf
Repetitive rTMS combined with cognitive training is a safe and effective modality for the treatment of Alzheimer disease-a randomized double Blind Study (Rabey, 2012).pdf
Treatment of Alzheimer disease with rTMS combined with cognitive training-a prospective randomized double-blind placebo controlled study (A. Lee, 2015).pdf
Repetitive transcranial magnetic stimulation combined with cognitive training in Alzheimer disease-Study poster (A. Lee, AAIC, 2016).pdf
Repetitive TMS combined with cognitive training is a safe and effective modality for the treatment of Alzheimer disease-clinical experience (Rabey, 2016).pdf
neuroAD is an investigational device currently not commercially available in the United States.
neuroAD is CE-cleared and commercially available for the treatment of mild to moderate Alzheimer’s Disease in Europe.